New Fertility Test Assesses Ovarian Reserve for Pregnancy
By LabMedica International staff writers Posted on 16 Oct 2014 |
A new anti-Müllerian Hormone (AMH) fertility test increases the accuracy of ovarian reserve assessment compared to conventional methods as AMH is an important fertility marker used by healthcare professionals to assess ovarian reserve levels.
The AMH blood test can be measured during any day of the menstrual cycle and is a superior indicator of ovarian reserve as compared to the follicle-stimulating hormone (FSH) and estradiol. In addition, the AMH blood test produces standardized results for assessing ovarian reserve as compared with the use of ultrasound, in which the result is often dependent on the operator or clinic.
The Elecsys Anti-Müllerian Hormone (AMH) blood test (Roche Diagnostics; Basel, Switzerland) is the first fully-automated AMH test for assessing a woman’s ovarian reserve. Elecsys AMH is a monoclonal two-site assay used to measure AMH in 50 µL of serum or lithium heparin plasma in about 18 minutes. Its measuring range is from 0.01 to 23 ng/mL. The assay detects primarily 140 kDa total AMH (proAMH and AMHN, C). Limit of detection (LoD) was 0.01 ng/mL equivalent to a limit of quantitation (LoQ) of (0.03 ng/mL. Percent recovery in dilution studies was less than 10% and after mixing of high and low AMH pools 94% to 103%. The highly sensitive, fast and fully automated AMH assay was developed for use on the Elecsys cobas e electrochemiluminescence immunoassay platform.
In the future, the Elecsys AMH assay is also intended to be used in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment, currently in phase III development at Ferring Pharmaceuticals (Saint Prex, Switzerland). This combination, which will make possible individualized dosing of human rFSH based on a woman’s specific AMH level, may provide an improved option for couples seeking to conceive through in vitro fertilization.
Roland Diggelmann, chief operating officer of Roche Diagnostics, said, “The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice while getting more reliable results faster than conventional protocols and manual AMH assays. It is an important example of our focus on improving diagnostics in the area of women’s health.”
Roche Diagnostics
Ferring Pharmaceutical
Related Links:
The AMH blood test can be measured during any day of the menstrual cycle and is a superior indicator of ovarian reserve as compared to the follicle-stimulating hormone (FSH) and estradiol. In addition, the AMH blood test produces standardized results for assessing ovarian reserve as compared with the use of ultrasound, in which the result is often dependent on the operator or clinic.
The Elecsys Anti-Müllerian Hormone (AMH) blood test (Roche Diagnostics; Basel, Switzerland) is the first fully-automated AMH test for assessing a woman’s ovarian reserve. Elecsys AMH is a monoclonal two-site assay used to measure AMH in 50 µL of serum or lithium heparin plasma in about 18 minutes. Its measuring range is from 0.01 to 23 ng/mL. The assay detects primarily 140 kDa total AMH (proAMH and AMHN, C). Limit of detection (LoD) was 0.01 ng/mL equivalent to a limit of quantitation (LoQ) of (0.03 ng/mL. Percent recovery in dilution studies was less than 10% and after mixing of high and low AMH pools 94% to 103%. The highly sensitive, fast and fully automated AMH assay was developed for use on the Elecsys cobas e electrochemiluminescence immunoassay platform.
In the future, the Elecsys AMH assay is also intended to be used in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment, currently in phase III development at Ferring Pharmaceuticals (Saint Prex, Switzerland). This combination, which will make possible individualized dosing of human rFSH based on a woman’s specific AMH level, may provide an improved option for couples seeking to conceive through in vitro fertilization.
Roland Diggelmann, chief operating officer of Roche Diagnostics, said, “The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice while getting more reliable results faster than conventional protocols and manual AMH assays. It is an important example of our focus on improving diagnostics in the area of women’s health.”
Roche Diagnostics
Ferring Pharmaceutical
Related Links:
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms